CClinicalTrials.gg
CompletedNCT05137561PROBIOPUpdated Aug 7, 2025

Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)

A Phase 2/3 interventional study of PSMA PET guided prostate biopsy and MRI directed TRUS guided prostate biopsy in Prostate Cancer and Prostate Neoplasm, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Completed at 1 site in India. Open to male participants aged 45 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Phase 2/3, Interventional, and Diagnostic

Phase
Phase 2/3
Study type
Interventional
Enrollment
217
Allocation
Randomized
Ages
45 Years to 90 Years
Sex
Male
01

Study summary

The present study aimed to compare the diagnostic accuracy, radiation exposure, complication rates between 68Ga-PSMA PET/CT guided robotic arm assisted prostate biopsy and MRI directed TRUS guided prostate biopsy in PIRADS 4/5 lesions.

Read the detailed description

To compare the diagnostic yield of Robotic-arm assisted 68Ga PSMA PET/CT guided prostate biopsy and MRI directed TRUS guided prostate biopsy in patients with PIRADS grading 4/5.

To compare the visual pain index of the patients between two arms during the procedure.

To compare the complication rates between the two arms during and after the procedure for a period of 2 weeks

02

Conditions studied

  • Prostate Cancer
  • Prostate Neoplasm

Browse trials for

03

In context

Prostatic Neoplasms

6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.

This study's enrollment of 217 is above the median of 58 across 4,822 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Post Graduate Institute of Medical Education and Research, Chandigarh is the lead sponsor of 290 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 90 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  1. PIRADS 4 and 5 prostate lesions and PIRADS \</= 3 prostate lesions with high clinical suspicion.
  2. Patients who are included in the study will be randomly allocated into either PSMA PET/CT guided biopsy or TRUS guided biopsy using simple randomization in RRApp

Exclusion criteria

Exclusion Criteria:

  1. Patients with acute prostatitis/ urine culture positive.
  2. Patients with pre-existing bleeding diathesis like hemophilia, coagulopathy defined by INR ≥ 1.2, and Platelet counts ≤ 80,000/mm3
  3. Patients who refuse to provide the written informed consent
  4. Non-cooperative patients
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
217 participants (actual)

Study arms

  • Active comparator
    PSMA PET/CT guided biopsy arm

    PSMA PET/CT guided biopsy will be done from PSMA avid lesion of the prostate after reviewing the whole body PSMA PET/CT scan.

    Procedure: PSMA PET guided prostate biopsy

  • Active comparator
    MRI directed TRUS guided biopsy

    The MRI-directed transrectal ultrasound-guided per-rectal prostate biopsy will be done by cognitive fusion.

    Procedure: MRI directed TRUS guided prostate biopsy

Interventions

  • ProcedurePSMA PET guided prostate biopsy

    PSMA PET-guided prostate biopsy from PSMA avid prostatic lesion will be done.

  • ProcedureMRI directed TRUS guided prostate biopsy

    TRUS guided MR directed Cognitive fusion prostate biopsy based on the PIRADS scoring

06

What researchers measure

Primary outcomes

  1. Diagnostic yield of mpMRI directed vs PET/CT directed prostate biopsy

    The number of participants (with percentages) in whom the biopsy procedure yielded a tissue specimen adequate for a definite pathological diagnosis and detection of PCa in both arms

    Time frame: 12 months

  2. Diagnostic performance of mpMRI directed vs PET/CT directed prostate biopsy

    The sensitivity, specificity and accuracy of mpMR directed TRUS guided (cognitive fusion) and PSMA PET/CT directed biopsy will be compared.

    Time frame: 12 months

Secondary outcomes

  1. Incidence of procedure related complications

    The procedure-related complications in the number and percentage of recruiting participants will be tabulated.

    Time frame: three months

07

Study locations

1 site
  • PGIMER
    Chandigarh, Chandigarh 160012, India
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05137561
Lead sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Responsible party
Rajender Kumar (Additional Professor, Post Graduate Institute of Medical Education and Research, Chandigarh) — Principal investigator
First posted
Nov 30, 2021
Start date
Oct 25, 2021
Primary completion
Jun 30, 2024
Completion
Jun 30, 2024
Last update
Aug 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion